A5020000878- Prostate Cancer Treatment and Research
- Medical Imaging Techniques and Applications
- Prostate Cancer Diagnosis and Treatment
- Radiation Dose and Imaging
- Cancer Immunotherapy and Biomarkers
- Genetic factors in colorectal cancer
- Advanced Radiotherapy Techniques
- PARP inhibition in cancer therapy
- Advanced X-ray and CT Imaging
- Monoclonal and Polyclonal Antibodies Research
- Cancer Diagnosis and Treatment
- Radiation Detection and Scintillator Technologies
- Digital Radiography and Breast Imaging
- Bladder and Urothelial Cancer Treatments
- Radiopharmaceutical Chemistry and Applications
- Radiomics and Machine Learning in Medical Imaging
- Nuclear Physics and Applications
- Hormonal and reproductive studies
- Sexual Differentiation and Disorders
- DNA Repair Mechanisms
- Breast Cancer Treatment Studies
- Renal cell carcinoma treatment
- Nonmelanoma Skin Cancer Studies
- Cancer Treatment and Pharmacology
- Cancer, Lipids, and Metabolism
University of Colorado Cancer Center
2023-2025
University of Colorado Denver
2021-2025
University of Colorado Anschutz Medical Campus
2021-2025
The Medical Center of Aurora
2025
Colorado Mesa University
2024
Fred Hutch Cancer Center
2018-2021
University of Washington
2016-2021
University of Washington Medical Center
2020
Moffitt Cancer Center
2020
Rush University Medical Center
2013-2017
Background While response rates to anti-PD1 therapy are low in unselected metastatic castration resistant prostate cancer (mCRPC) patients, those with inactivating mutations mismatch repair (MMR) genes (i.e. MMR deficiency; MMRd) or microsatellite instability (MSI) thought likely respond favorably. To date, there is limited published data on this biologically distinct and clinically relevant subgroup's natural history treatment. Methods We retrospectively identified patients at two academic...
PURPOSE There are limited data available on the real-world patterns of molecular testing in men with advanced prostate cancer. We thus sought to evaluate next-generation sequencing (NGS) United States, focused single versus serial NGS testing, different disease states (hormone-sensitive v castration-resistant, metastatic vs nonmetastatic), tissue plasma circulating tumor DNA (ctDNA) assays, and how often actionable were found each test. METHODS The Prostate Cancer Precision Medicine...
625 Background: Erdafitinib (E) is a treatment option in mUCpatients with somatic FGFR2/3 GAs after progression on platinum-based chemotherapy (PBC). Enfortumab Vedotin (EV) approved as single agent to treat mUC patients following prior PBC and PD1/L1 inhibitors or second-line therapy for cisplatin-ineligible patients. Retrospective studies suggest that the activity of EV not compromised by GAs. E have different mechanisms activity, toxicities are mostly non-overlapping. Hence, there...
While
PURPOSE Outcomes data for DNA-damaging therapeutics men with prostate cancer (PC) and non- BRCA1/2 homologous recombination repair (HRR) mutations are limited. We evaluated outcomes by HRR alteration in PC treated poly(ADP-ribose)polymerase inhibitors (PARPi) and/or platinum chemotherapy. METHODS Retrospective from the PROMISE consortium were used. Clinical differences assessed between patients BRCA1/ 2 (cohort A) those without direct BRCA complex interaction B: ATM, CDK12, CHEK1, CHEK2,...
Androgen-indifferent prostate cancer (AIPC) is increasingly common and particularly lethal. Data describing these tumors are sparse, AIPC remains a poorly understood malignancy. Utilizing the Oncology Research Information Exchange Network (ORIEN) database, we enriched for with features of using previously described characteristics. Our cohort included three subgroups: aggressive variant (AVPC), neuroendocrine PC (NEPC), double-negative (DNPC). Of 1496 total patients available analysis,...
The use of supraphysiologic testosterone, particularly when alternated with an anti-androgen agent in men metastatic castration-resistant prostate cancer (CRPC), has demonstrated promising results clinical trials. As the this therapy practice is more widely adopted, there will be a growing need to understand mechanisms resistance. To that end, we independently derived three separate cell models testosterone-sensitive CRPC. From each CRPC line, high dose testosterone-resistance (HTR) lines...
222 Background: Androgen indifferent prostate cancer (AIPC) is increasingly common and particularly lethal. Data describing these tumors are sparse AIPC remains a poorly understood malignancy. This study aims to characterize the clinical genomic features of AIPC. Our work ultimately seeks identify biomarkers with diagnostic therapeutic potential. Methods: Utilizing Oncology Research Information Exchange Network (ORIEN) database, we queried all (PC) patients, identified metastatic castrate...
808 Background: Erdafitinib (E) is an approved treatment in patients with mUCwith FGFR 3 GAs after progression on platinum-based chemotherapy (PBC). Enfortumab Vedotin (EV) to treat mUC following prior PBC and PD1/L1 inhibitors or as First-line therapy combination pembrolizumab. Retrospective studies suggest that the activity of EV not compromised by 3/2 GAs. erdafitinib have different mechanisms toxicities are mostly non-overlapping. Hence, there rationale evaluate feasibility E, overcome...
The NCCN Guidelines for Testicular Cancer provide recommendations the multidisciplinary approach to diagnostic workup, treatment, and follow-up testicular germ cell tumors, including both seminoma nonseminoma. These Insights discuss current treatment supporting clinical data seminomas as presented in Version 2.2025 of Cancer.
To determine if in vivo binding specificities of monoclonal antibodies to tumor nodules would reflect vitro antibody as determined by radioimmunoassay, two were selected for imaging human xenografts nude mice. By 436 binds the M20 melanoma cell line, but not P3 carcinoma line; 44 M20. Both are IgG1 isotypes. Nude mice bearing an one flank and a other injected intravenously with 5 25 μg each labeled either I-125 or I-131; separate animals labels reversed. Animals imaged daily scintillation...
Abstract Background Amphicrine prostate carcinoma (AMPC) is a poorly defined subset of cancer in which cells co‐express luminal epithelial and neuroendocrine markers. The optimal treatment strategy unknown. We sought to further characterize the clinical, histomorphologic, molecular characteristics AMPC identify areas potential future investigations. Methods retrospectively identified 17 cases at single institution, as synaptophysin expression >70% co‐expression androgen receptor (AR)...
A comprehensive performance testing program is an essential ingredient of high‐quality single‐photon emission computed tomography (SPECT). Many the procedures previously published are complicated, time consuming, or require a special environment. This Task Group developed protocol for evaluating SPECT imaging systems that was simple, practical, required minimal test equipment, and could be performed in few hours using processing software available on all nuclear medicine computers. It...
Abstract Mutational burden is positively correlated with tumor neoantigen load and studies have demonstrated an association between high mutational (TMB) response to checkpoint blockade. On the basis of a phase II study, anti-PD-1 therapy, pembrolizumab, was given FDA approval for use in any solid TMB (i.e., >10 mutations/megabase) as assessed by FoundationOne companion diagnostic. This important step expanding potentially efficacious treatment option patients who are likely benefit...
The Intermittent Exotropia Questionnaire (IXTQ) is a patient, proxy, and parental report of quality life specific to children with intermittent exotropia. We refine the IXTQ using Rasch analysis improve reliability validity.Rasch was performed on responses 575 patients exotropia enrolled from May 15, 2008, through July 24, 2013, their parents each 4 health-related quality-of-life questionnaires (child 5 7 years age child 8 17 age, parent questionnaires). performance structure were confirmed...
Abstract Background AR gene alterations can develop in response to pressure of testosterone suppression and androgen receptor targeting agents (ARTA). Despite this, the relevance these context ARTA treatment clinical outcomes remains unclear. Methods Patients with castration-resistant prostate cancer (CRPC) who had undergone genomic testing received were identified Prostate Cancer Precision Medicine Multi-Institutional Collaborative Effort (PROMISE) database. stratified according timing...